<DOC>
	<DOCNO>NCT03069989</DOCNO>
	<brief_summary>GSK3008348 develop treatment IPF . A first-time-in-human study show single nebulized dos 1âˆ’3000 microgram ( mcg ) GSK3008348 healthy volunteer well tolerate , pharmacokinetic ( PK ) exposures within defined limit set protocol . The propose study 2-cohort study single dos , intend evaluate safety , tolerability PK drug participant IPF currently treat pirfenidone nintedanib , obtain preliminary information target engagement . Cohort 1 2-period , randomize , double-blind , placebo-controlled group least 7 day washout dos , follow-up period 7-14 day . Cohort 2 optional . It design explore safety provide additional information target engagement profile GSK3008348 . The total duration study 62 day .</brief_summary>
	<brief_title>Single Doses GSK3008348 Idiopathic Pulmonary Fibrosis ( IPF ) Participants Using Positron Emission Tomography ( PET ) Imaging</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>Male participant age &gt; = 50 year , female participant age &gt; =55 year , time signing informed consent . Diagnosis definite probable IPF determine responsible experienced chest physician base establish criterion define American Thoracic Society/European Respiratory Society Internationale Multidisciplinary Consensus Classification Idiopathic Interstitial Pneumonias . Ambulant capable attend outpatient visit . FVC &gt; 50 percent predict DLCO &gt; 40 percent predict . Body weight &gt; = 45 kilogram ( kg ) body mass index ( BMI ) within range 18.035.0 kg/square meter ( inclusive ) . Male female Male participant : A male participant must agree use contraception detail protocol study least 90 day follow visit , refrain donate sperm period . Female participant : A female participant eligible participate pregnant , breastfeeding , woman childbearing potential ( WOCBP ) define protocol . Capable give sign informed consent , include compliance requirement restriction , list informed consent form ( ICF ) protocol . ALT bilirubin &gt; 1.5x upper limit normal ( ULN ; isolate bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 percent ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . QT correct ( QTc ) &gt; 450 millisecond ( msec ) , QTc &gt; 480 msec participant Bundle Branch Block . Current IPF exacerbation , upper low respiratory tract infection admission clinical unit . History suffers claustrophobia , unable lie flat still back 2 hr PET scanner . Extent emphysema great extent fibrotic change HighResolution Computed Tomography ( HRCT ) scan , base investigator judgment . FEV1/FVC ratio &lt; 0.70 screening ( postbronchodilator ) . History sensitivity study treatment , component thereof , history drug allergy , opinion investigator Medical Monitor , contraindicate participation . Any current oropharygneal disease disorder judge investigator . Currently take pirfenidone nintedanib , receive pirfenidone nintedanib within 30 day first dose study treatment . Taken , within 7 day 5 halflives ( whichever longer ) first dose study treatment , organic anion transporter ( OAT ) substrates narrow therapeutic index ( example : methotrexate tenofovir ) , vitamin , dietary herbal supplement , unless opinion investigator sponsor supplement interfere study medication . Longterm continuous home oxygen therapy ( use oxygen intermittent symptom relief acceptable ) . Participation clinical trial receipt investigational medicinal product within following time period first dose current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure 4 new investigational medicinal product within 12 month first dose . Presence Hepatitis B surface antigen ( HBsAg ) screening , positive Hepatitis C antibody test result screen within 3 month first dose study treatment . Note : participant positive Hepatitis C antibody test previous , resolve disease enrol confirmatory negative Hepatitis C Ribonucleic Acid ( RNA ) test obtain . Previous current exposure animal may harbour Food Mouth Disease Virus ( FMDV2 ) . Previous long term ( &gt; = 3 month ) residence country FMDV2 endemic ( certain area Africa , Asia South America . Where participation study would result loss blood blood product excess 500 milliliter ( mL ) within 56 day . History drug alcohol abuse opinion investigator affect participation study . Exposure ionize radiation excess 10 Millisievert ( mSv ) background previous 3 year period result occupational exposure previous participation research study . Clinically justified ( therapeutic diagnostic ) exposures included exposure calculation .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Tolerability</keyword>
	<keyword>IPF</keyword>
	<keyword>PET image</keyword>
	<keyword>Idiopathic Pulmonary Fibrosis</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Double-blind</keyword>
</DOC>